Moderna Inc MRNA-Q on Thursday raised its full-year forecast for sales of its COVID-19 vaccine to roughly $21-billion from $19-billion.
The company in February forecast sales of $19-billion from its signed contracts, and option for $3-billion in additional purchases.
Moderna on Thursday forecast additional purchases of roughly $500-million.
Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.